Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease.
Shepp DH, Ramirez-Ronda C, Dall L, Pollard RB, Murphy RL, Kessler H, Sherer R, Mertz G, Perez G, Gocke DJ, Greenberg SB, Petersen E, Frank I, Moore MD, McKinnis R, Rooney JF. Shepp DH, et al. Among authors: pollard rb. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):283-8. doi: 10.1097/00042560-199708010-00006. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9292587 Clinical Trial.
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L. Spruance SL, et al. Ann Intern Med. 1994 Mar 1;120(5):360-8. doi: 10.7326/0003-4819-120-5-199403010-00002. Ann Intern Med. 1994. PMID: 7905722 Clinical Trial.
In vivo antagonism with zidovudine plus stavudine combination therapy.
Havlir DV, Tierney C, Friedland GH, Pollard RB, Smeaton L, Sommadossi JP, Fox L, Kessler H, Fife KH, Richman DD. Havlir DV, et al. Among authors: pollard rb. J Infect Dis. 2000 Jul;182(1):321-5. doi: 10.1086/315683. Epub 2000 Jul 6. J Infect Dis. 2000. PMID: 10882616 Clinical Trial.
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M. Friedland GH, et al. J Acquir Immune Defic Syndr. 1999 Aug 1;21(4):281-92. doi: 10.1097/00126334-199908010-00005. J Acquir Immune Defic Syndr. 1999. PMID: 10428106 Clinical Trial.
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team. Sax PE, et al. J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505. J Infect Dis. 2011. PMID: 21917892 Free PMC article. Clinical Trial.
A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS. Japour AJ, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):235-46. doi: 10.1097/00042560-199611010-00005. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8898668 Clinical Trial.
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. Lennox JL, et al. Among authors: pollard rb. J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. J Acquir Immune Defic Syndr. 2010. PMID: 20404738 Free PMC article. Clinical Trial.
245 results